Background: Autoantibodies can be identified in approximately 60% of UK children with JDM. With the development of quantitative techniques such as ELISA to detect these autoantibodies there is a growing interest in the clinical utility of autoantibodies in predicting disease activity and the risk of associated complications. To date, the titre of anti-MDA5 has been shown to be useful in predicting response to treatment in Japanese children with JDM and in adults small studies have also shown a relationship between the titres of anti-Jo-1, anti-MDA5, anti-HMGCR and anti-SRP with disease activity measures. Methods: Serum samples and matched clinical data were obtained from 285 patients with JDM recruited to the UK Juvenile Dermatomyositis Cohort and Biomarker Study. After initial screening for the presence of autoantibodies by immunoprecipitation, the antibody titre of those with anti-TIF1g, anti-NXP2 and anti-MDA5 was assessed by ELISA using recombinant antigen. First and last available samples were analysed for each autoantibody subgroup (32 patients with anti-TIF1g, 30 with anti-NXP2 and 15 with anti-MDA5) along with multiple serial samples in those where an initial sample was available within 6 months of diagnosis (12 patients with anti-TIF1g, 8 with anti-NXP2 and with 4 anti-MDA5). Between three and eight samples were available per patient. Results: Autoantibody titre was seen to change over the follow-up period and reduced in the majority of patients in all autoantibody subgroups. In the last available sample (taken 1-19 years post diagnosis) autoantibody titre had reduced below the ELISA positive threshold in eight (25%) patients with anti-TIF1g, seven (23%) with anti-NXP2 and eight (53%) with anti-MDA5.
Background: Immunosuppressive are commonly used in SLE during pregnancy to ensure optimum outcome for mother and child. However, there is little literature regarding long-term outcomes of these children. This study aims to assess if HCQ is associated with any adverse outcomes. Methods: Women attending lupus clinics, with available pregnancy data, were consented to take part. A standard questionnaire developed for a multi-centre study was used to collect the data. Results: Complete data were available for 288 children born alive to 200 women: 66% Caucasian, 15% South Asian, 10%Afro-Caribbean, 1% Chinese, 1% Hispanic 4% other and 4% not stated. The median (range) age of women at delivery was 32 (19-44) years, and duration of disease was 6 (0.5-27) years.
Two groups were studied: 149 children exposed to HCQ during pregnancy &/or breast feeding vs 139 children unexposed. No statistically significant differences in exposure to prednisolone, azathioprine, aspirin or heparin between the groups was identified. Median age of children at enrolment exposed to HCQ was 2.1 (0-17.1) vs 4.6 (0.13-17.0) years in unexposed. There was no significant difference in maternal pre-eclampsia between the two groups 16/142 (11%) vs 12/128 (9%), P ¼ 0.75. The prevalence of anti-Ro &/or anti-La antibodies was 50/135 (37%) in exposed vs 61/127 (48%) in unexposed group, P ¼ 0.94. The presence of maternal lupus anticoagulant and/or anticardiolipin antibodies was 69/128 (54%) vs 54/122 (44%), P ¼ 0.16.
Median gestational age at delivery was 38 weeks in both groups (range 25-42 for exposed, 27-41 weeks for non-exposed group). There was no statistical difference in birth weight between the groups-mean 2.8 kg in both groups. Congenital anomalies were categorized using the EUROCAT (European surveillance of Congenital Anomalies) definitions, only major anomalies were analysed. There was no difference in frequency of anomalies including congenital heart block, hospital visits or developmental problems but HCQ appeared to protect against hospital admission for infection and out-patient visits (Table 1) . Conclusion: This study confirms that HCQ use in pregnancy &/or breastfeeding is not associated with any adverse long-term outcomes in children born to mothers with SLE. Disclosure statement: The authors have declared no conflicts of interest. All children ¼ 286, n (%) Children exposed to HCQ during pregnancy and/or breast feeding ¼ 149, n (%)
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Children not exposed to HCQ during pregnancy and/or breast feeding ¼ 138, n (%)
P-value
Congenital heart block 7/287 (2. 
